Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A Protease

被引:42
|
作者
Romano, Keith P. [1 ]
Laine, Jennifer M. [1 ]
Deveau, Laura M. [1 ]
Cao, Hong [1 ]
Massi, Francesca [1 ]
Schiffer, Celia A. [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
CRYSTAL-STRUCTURE; INHIBITOR; REPLICATION; VARIANTS; CLEAVAGE;
D O I
10.1128/JVI.00377-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C NS3/4A protease is a prime therapeutic target that is responsible for cleaving the viral polyprotein at junctions 3-4A, 4A4B, 4B5A, and 5A5B and two host cell adaptor proteins of the innate immune response, TRIF and MAVS. In this study, NS3/4A crystal structures of both host cell cleavage sites were determined and compared to the crystal structures of viral substrates. Two distinct protease conformations were observed and correlated with substrate specificity: (i) 3-4A, 4A4B, 5A5B, and MAVS, which are processed more efficiently by the protease, form extensive electrostatic networks when in complex with the protease, and (ii) TRIF and 4B5A, which contain polyproline motifs in their full-length sequences, do not form electrostatic networks in their crystal complexes. These findings provide mechanistic insights into NS3/4A substrate recognition, which may assist in a more rational approach to inhibitor design in the face of the rapid acquisition of resistance.
引用
收藏
页码:6106 / 6116
页数:11
相关论文
共 50 条
  • [31] Analysing drug resistance in terms of substrate recognition in HCV NS3/4A protease
    Romano, K.
    Schiffer, C.
    ANTIVIRAL THERAPY, 2009, 14 (04) : A36 - A36
  • [32] Development of cell-based assays for in vitro characterization of hepatitis C virus NS3/4A protease inhibitors
    Chung, V
    Carroll, AR
    Gray, NM
    Parry, NR
    Thommes, PA
    Viner, KC
    D'Souza, EA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (04) : 1381 - 1390
  • [33] High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors
    Lee, JC
    Yu, MC
    Lien, TW
    Chang, CF
    Hsu, JTA
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2005, 3 (04) : 385 - 392
  • [34] Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease
    Sheng, X. Christopher
    Appleby, Todd
    Butler, Thomas
    Cai, Ruby
    Chen, Xiaowu
    Cho, Aesop
    Clarke, Michael O.
    Cottell, Jeromy
    Delaney, William E.
    Doerffler, Edward
    Link, John
    Ji, Mingzhe
    Pakdaman, Rowchanak
    Pyun, Hyung-Jung
    Wu, Qiaoyin
    Xu, Jie
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) : 2629 - 2634
  • [35] Furaprevir HCV NS3/4A protease inhibitor Treatment of chronic hepatitis C virus infection
    Ghosh, Prithwish
    Nehra, Vandana
    Temesgen, Zelalem
    DRUGS OF THE FUTURE, 2022, 47 (08) : 557 - 565
  • [36] Inhibitors of hepatitis C virus NS3•4A protease 2.: Warhead SAR and optimization
    Perni, RB
    Pitlik, J
    Britt, SD
    Court, JJ
    Courtney, LF
    Deininger, DD
    Farmer, LJ
    Gates, CA
    Harbeson, SL
    Levin, RB
    Lin, C
    Lin, K
    Moon, YC
    Luong, YP
    O'Malley, ET
    Rao, BG
    Thomson, JA
    Tung, RD
    Van Drie, JH
    Wei, YY
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (06) : 1441 - 1446
  • [37] Virtual Screening of Telaprevir and Danoprevir Derivatives for Hepatitis C Virus NS3/4A Protease Inhibitors
    Sarkar, Kaushik
    Das, Rajesh Kumar
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (04) : 809 - 822
  • [38] Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
    Harper, Steven
    McCauley, John A.
    Rudd, Michael T.
    Ferrara, Marco
    DiFilippo, Marcello
    Crescenzi, Benedetta
    Koch, Uwe
    Petrocchi, Alessia
    Holloway, M. Katharine
    Butcher, John W.
    Romano, Joseph J.
    Bush, Kimberly J.
    Gilbert, Kevin F.
    McIntyre, Charles J.
    Nguyen, Kevin T.
    Nizi, Emanuela
    Carroll, Steven S.
    Ludmerer, Steven W.
    Burlein, Christine
    DiMuzio, Jillian M.
    Graham, Donald J.
    McHale, Carolyn M.
    Stahlhut, Mark W.
    Olsen, David B.
    Monteagudo, Edith
    Cianetti, Simona
    Giuliano, Claudio
    Pucci, Vincenzo
    Trainor, Nicole
    Fandozzi, Christine M.
    Rowley, Michael
    Coleman, Paul J.
    Vacca, Joseph P.
    Summa, Vincenzo
    Liverton, Nigel J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (04): : 332 - 336
  • [39] Inhibitors of hepatitis C virus NS3•4A protease:: P2 proline variants
    Farmer, LJ
    Britt, SD
    Cottrell, KM
    Court, JJ
    Courtney, LF
    Deininger, DD
    Gates, CA
    Harbeson, SL
    Lin, K
    Lin, C
    Luong, YP
    Maxwell, JP
    Pitlik, J
    Rao, BG
    Schairer, WC
    Thomson, JA
    Tung, RD
    Van Drie, JH
    Wei, YY
    Perni, RB
    LETTERS IN DRUG DESIGN & DISCOVERY, 2005, 2 (07) : 497 - 502
  • [40] MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
    Liverton, Nigel J.
    Carroll, Steven S.
    DiMuzio, Jillian
    Fandozzi, Christine
    Graham, Donald J.
    Hazuda, Daria
    Holloway, M. Katherine
    Ludmerer, Steven W.
    McCauley, John A.
    McIntyre, Charles J.
    Olsen, David B.
    Rudd, Michael T.
    Stahlhut, Mark
    Vacca, Joseph P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 305 - 311